+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07286058

Long-Term Extension Study Evaluating Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis Previously Treated in Parent Studies

Led by Takeda · Updated on 2026-09-09

1182

Participants Needed

78

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Psoriatic arthritis PsA is a chronic inflammatory condition affecting joints and skin. This Phase 3 study aims to assess the long-term safety, tolerability, and effectiveness of the drug zasocitinib in adults with active PsA. It includes adults who have completed a previous year-long treatment in related parent studies and evaluates continued treatment over an extended period. Participants who previously took zasocitinib will maintain their assigned dose, while those initially on a different treatment will be randomly assigned to one of two doses of zasocitinib, taken once daily as oral tablets. The study treatment phase lasts up to 104 weeks, followed by a 4-week health monitoring period, totaling about 2 years of participation. During the study, participants will be regularly monitored for side effects, vital signs, and lab tests to assess safety. Researchers will also evaluate treatment effectiveness using criteria like the American College of Rheumatology response and skin improvement scores at multiple time points. After treatment, a follow-up period will ensure participants health is observed for any ongoing effects.

CONDITIONS

Brief Title

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Research Team

T

Takeda Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here